Publicações

Pembrolizumab Versus Methotrexate, Docetaxel, or Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (Keynote-040) : Subgroup Analysis by Pattern of Disease Recurrence

AuthID
P-00Z-C2R

Author(s)

Harrington, KJ

Cohen, EEW

Soulières, D

Dinis, J

Licitra, L

Ahn, MJ

Soria, A

Machiels, JP

Mach, N

Mehra, R

Burtness, B

Swaby, RF

Lin, J

Ge, J

Lerman, N

Le Tourneau, C

Tipo de Documento

Article

Year published

2023

Publicado

in ORAL ONCOLOGY, ISSN: 1368-8375

Volume: 147

Indexing

Wos^®

Scopus^®

Pubmed^®

Google Scholar^®

Metadata
Fontes

Publication Identifiers

DOI: 10.1016/j.oraloncology.2023.106587

Pubmed: 37925894

SCOPUS: 2-s2.0-85175709609

Wos: WOS:001108199800001

Source Identifiers

ISSN: 1368-8375

Export Publication Metadata

Lista Marked

Adicionar à lista Marked

Info

At this moment we don't have any links to full text documens.

Pembrolizumab Versus Methotrexate, Docetaxel, or Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (Keynote-040) : Subgroup Analysis by Pattern of Disease Recurrence

Links Úteis

Ajuda

Autenticação Federada (Clique na imagem)

Pembrolizumab Versus Methotrexate, Docetaxel, or Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (Keynote-040) : Subgroup Analysis by Pattern of Disease Recurrence

Links Úteis

Ajuda